Direct efficiency of different modes of scheme “paclitaxel Caelyx” in the treatment of patients having inflammatory breast cancer

Abstract

Inflammatory breast cancer (IBC) with a poor prognosis occurs in 1-5% of patients with breast cancer. Combination of Paclitaxel and Caelyx were applied for 42 patients with IBC with the use of 2 regimens. Paclitaxel-135 mg/m² 1 day, Caelyx 40 mg/m² 1day within a cycle of 3 weeks (21 sick women); the weekly regimen has a scheme: 60 mg/m² on 1st, 8th and15th days and Caelyx-25 mg/m² on 1st, 8th days within a cycle of 4 weeks (21 sick women). The final analysis of the effectiveness of 2 chemotherapy regimens showed that an objective impact was reached in 85.7% (18/21) in the group of weekly insertion of the drugs by the end of the research; and in the group of routine chemotherapy it was 52.4% (11/21). Though general results are satisfactory in both 2 regimens of the chemotherapy, the weekly insertion of the drugs let to decrease a hematologic toxicity of 3-4 degree in 2.5-3 times and a frequency of LPS in 10 times.